A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) with Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed and Refractory Hematologic Malignancies

Study Overview

The purposes of this study are to: (1) find the most effective dose of a new type of radiation therapy called total marrow irradiation (TMI) that will be given with the conditioning chemotherapy, fludarabine, to prepare patients for allogeneic hematopoietic stem cell transplantation (Allo-HSCT); and (2) see if utilization of TMI in place of total body irradiation (TBI) will reduce side effects by giving less radiation to organs at risk.

Study Description

The purpose of this study is to find the most effective dose of a new type of radiation therapy called total marrow irradiation (TMI) that is given with a type of chemotherapy called fludarabine to prepare patients for allogeneic hematopoietic stem cell transplantation (Allo-HSCT).

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1803628152 (IUSCC-0652)
  • Research Study Identifier: TX9082
  • Principal Investigator: Naoyuki Saito, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.